DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "The Market For Cell Therapy Manufacturing - Strategies for Pricing, Cost Control, Reimbursement, Distribution, & More" report to their offering.
This global strategic report provides detailed analysis of ten leading cell therapy companies worldwide, evaluating the strengths of each company, as well as identifying cell therapy products in development, manufacturing strategies, and partnerships.
The report analyzes time frames for cell therapy product development, distribution channels, key trends and technologies impacting cell therapy manufacturing, cost control measures, and challenges and considerations affecting with cell therapy manufacturing.
Additionally, the report identifies cell therapy products that have been reviewed and approved by internationally-recognized regulatory agencies, as well as products brought to market in the U.S. with FDA approval. It also specifies which cell therapies have since been pulled from market, due to factors such as low adoption rates, unsuccessful reimbursement strategies, or high cost of manufacturing.
It provides an overview of the regulatory environment affecting cell therapy manufacturing in key countries worldwide, evaluating the importance of the recent FDA guidelines for Human Cell and Tissue-based Products (HCT/Ps) and the 21st Century Cures Act, as well as accelerated pathways for cell therapy approvals in Japan, including the:
- Act on the Safety of Regenerative Medicine (Law No. 85/2013)
- Pharmaceuticals and Medical Device (PMD) Act (Law No. 84/2013)
Key Topics Covered:
1. Introduction to Cell Therapy Manufacturing
2. Leading Cell Therapy Companies
3. Approved Cell Therapy Products
4. Pricing Analysis for Cell Therapy Products
5. Cost-Control for Cell Therapy Products
6. Time Frames for Cell Therapy Product Development
7. Reimbursement of Cell Therapy Products
8. Distribution Channels for Cell Therapy Products
9. Market Trend Analysis - Key Trends Impacting the Marketplace
10. Technologies Impacting the Cell Therapy Manufacturing Market
11. Market Potential for Autologous vs. Allogeneic Manufacturing
12. Cell Therapy Manufacturing Challenges and Considerations
13. Conclusions
Cell Therapies Mentioned:
- Apligraf (Organogenesis, Inc. & Novartis AG)
- Carticel (Genzyme)
- Cartistem (MEDIPOST)
- ChrondoCelect (TiGenix NV)
- Cupistem (Anterogen)
- Dermagraft (Advanced Tissue Sciences)
- Epicel (Vericel)
- Hearticellgram-AMI (FCB Pharmicell)
- Holoclar (Chiesi Farmaceutici)
- Osteocel (NuVasive)
- Prochymal (Mesoblast)
- Provenge
- Strimvelis (GSK)
- TEMCELL (JCR Pharmaceuticals Co. Ltd., Licensee of Mesoblast Ltd.)
For more information about this report visit https://www.researchandmarkets.com/research/rspfrk/the_market_for
